Molecular Partners AG (SWX:MOLN)
Switzerland · Delayed Price · Currency is CHF 2.500
-0.010 (-0.40%)
Nov 12, 2026, 12:10 PM CET
Molecular Partners AG Revenue
Revenue
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
134
Market Cap
95.84M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | 4.97M | -2.07M | -29.38% |
| Dec 31, 2023 | 7.04M | -182.56M | -96.29% |
| Dec 31, 2022 | 189.60M | 179.85M | 1,843.82% |
| Dec 31, 2021 | 9.75M | 410.00K | 4.39% |
| Dec 31, 2020 | 9.34M | -11.04M | -54.16% |
| Dec 31, 2019 | 20.38M | 10.03M | 96.84% |
| Dec 31, 2018 | 10.36M | -9.66M | -48.27% |
| Dec 31, 2017 | 20.02M | -3.02M | -13.13% |
| Dec 31, 2016 | 23.04M | -6.08M | -20.88% |
| Dec 31, 2015 | 29.12M | 2.49M | 9.37% |
| Dec 31, 2014 | 26.63M | -5.79M | -17.87% |
| Dec 31, 2013 | 32.42M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Bachem Holding AG | 708.53M |
| Basilea Pharmaceutica AG | 247.42M |
| Idorsia | 220.15M |
| Santhera Pharmaceuticals Holding AG | 101.50M |
| Newron Pharmaceuticals | 9.62M |
| BioVersys AG | 4.62M |
| MindMaze Therapeutics Holding | 1.20M |
| Xlife Sciences AG | 397.23K |
Molecular Partners AG News
- 6 days ago - Molecular Partners Presents New Preclinical Data for Next-Generation T Cell Engager MP0632 at SITC 2026 - GlobeNewsWire
- 7 days ago - Molecular Partners to Present on DLL3-Targeting Radio-DARPin MP0712 at 2026 SNMMI Theranostics Conference and NACLC 2026 - GlobeNewsWire
- 14 days ago - Molecular Partners AG Earnings release: Q3 2026 - Filings
- 14 days ago - Molecular Partners AG Slides: Q3 2026 - Filings
- 14 days ago - Molecular Partners Reports Q3 2026 Financial Results, Deepens Focus on Targeted Radiotherapy - GlobeNewsWire
- 2 months ago - Molecular Partners AG Slides: Q2 2026 - Filings
- 2 months ago - Molecular Partners AG Earnings release: Q2 2026 - Filings
- 2 months ago - Molecular Partners Reports H1 2026 Financial Results and Corporate Highlights: DLL3 Radiotherapy MP0712 Successfully Advancing to Higher Dose Level in Phase 1/2a Study - GlobeNewsWire